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Summary 
Immunohistochemical  methods  were  used  to  search  for  Fas  receptor/Fas  ligand  system  in- 
volvement in multiple  sclerosis  (MS)  white  matter brain  lesions.  We found large numbers  of 
Fas ligand  (Fas-L)-bearing cells present in two acute lesions and  12  of 16  chronic  MS  lesions, 
and very few positive cells in non-inflammatory controls. Four of six brains from non-MS neu- 
ropathologic conditions associated with inflammation and white matter disease were, however, 
also positive for Fas-L. Double  staining with  cell-specific markers revealed that the pattern  of 
ligand-positive  cells in chronic MS lesions was complex and composed of several different cell 
types which were primarily resident glial cells with a small overlay ofmacrophages.  Fas/APO  1 
(CD95)  receptor expression in MS tissue was also evaluated and marked upregulation of the re- 
ceptor was found.  In addition,  Fas receptor was induced,  but  to a lesser extent,  in numerous 
control brains.  The observations that TUNEL-positive  dying cells were present in MS lesions 
and showed excellent co-localization  with  Fas-L, indicate  that the Fas death system may con- 
tribute  to plaque pathogenesis  and could lead to the development of a new category of thera- 
peutic agents for MS. 
M 
ultiple  sclerosis  (MS) 1 is  a  common  inflammatory 
disease of central nervous system white matter.  It is 
considered to be an autoimmune condition,  but the under- 
lying mechanisms of tissue injury and cell death are poorly 
understood  (1). Possible mechanisms of cytotoxicity in hu- 
man MS brain and the animal model, experimental allergic 
encephalomyelitis  (EAE),  have  been  studied  for  decades 
and  several  candidate  death  effectors  have  been  proposed 
(2, 3).  In recent years, bursts of T  cell-inflammatory cyto- 
kine production  before and  coincident  with  exacerbations 
of clinical  disease have been widely implicated as  effectors 
of tissue  injury in both MS  and EAE  (4,  5).  We  have re- 
cently used the in situ TUNEL  assay for fragmented DNA 
to demonstrate  that MS lesions often have substantial pop- 
ulations of inflammatory and resident glial cells undergoing 
cell  death.  Immunohistochemical  identification  of the  dy- 
ing cells with glial-specific marker co-labeling showed that 
14-40% were the myelin-sustaining oligodendroglial cell and 
the pattern  of electrophoresed  DNA  from some TUNEL- 
positive MS brains also displayed laddering characteristic  of 
apoptotic DNA cleavage (6). 
1Abbreviations used in this paper: EAE, experimental allergic encephalomy- 
elitis; GFAP, glial fibrillary acidic protein;  HNK, human  NK marker; 
MS, multiple sclerosis. 
In this  study,  we provide  the  first evidence  implicating 
the newly identified Fas/Apo  1 (CD95) receptor/Fas ligand 
(Fas-L)  cell death pathway in MS  lesion pathogenesis.  We 
show  that  Fas-L  is  widely  present  on  glial  cells  in  many 
chronic MS plaques and that white matter cells commonly 
carry receptors for this cytotoxin,  rendering them sensitive 
to attack as judged by DNA fragmentation studies and Fas-L 
co-localization. 
Materials  and Methods 
Autopsy  Specimens 
The study was performed on chronic MS plaques (n =  15) and 
control brains obtained from the Rocky Mountain Multiple Scle- 
rosis  Center  (Englewood,  CO),  the  MS  human  neurospecimen 
bank  (West Los Angeles,  CA)  and from material collected over 
the past 23 yr at St. Vincent' s Hospital (New York, NY). Two 
paraffin-embedded  acute  MS  plaques  obtained  from  Dr. John 
Prineas  (Newark, NJ) were also studied.  The average post-mor- 
tem interval for MS paraffin-embedded material was 17.8 h and 5 
were obtained within 7 h of death. The paraffin-embedded non- 
MS  control  brains  included  two  ALS  patients  whose  autopsies 
were performed within 3-6 h of death, HIV/AIDS encephalitis-2, 
Alzheimer's disease-I, cerebrovascular disease-i, Parkinson's dis- 
ease-l, progressive  multifocal  leucoencephalopathy (PML)-I, acute 
hemorrhagic leucoencephalitis  (AHLE)-I, glioblastoma multiformed 
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subacute sclerosing panencephalitis (SSPE)-I. 
Immunohistochemistry for Fas Ligand,  Fas Receptor, and In 
Situ  TUNEL Detection of Nuclear DNA Fragmentation. 
Fas-L Detection.  3-b~m paraffin embedded sections were attached 
to slides  precoated with vectorbond adhesive and dewaxed.  En- 
dogenous peroxidase  activity was  blocked by washing with  3% 
hydrogen peroxide  for  5  rain and antigenic sites  were  exposed 
by  immersion  in  target  unmasking  fluid  (TUF;  Signet  Labs, 
Deedham, MA)  preheated to  95~  for  10 min. The slides  were 
removed  from  the  water  bath  and  allowed  to  remain  in  the 
heated TUF solution for an additional 10 rain. The slides  were 
washed with PBS for 5 min ￿  and incubated overnight at 4~ 
with polyclonal anti-human Fas-L antibody at 0.5 btg/ml (Q20- 
Santa Cruz Biotechnology,  CA).  The  slides  were  again washed 
with PBS for 5  min ￿  and antibody-positive cells were visual- 
ized with diaminobenzidine after reaction with the Vector ABC 
detection kit following the manufacturer's instructions. Slides on 
which the primary antibody was omitted were used to control for 
non-specific binding. As a further test of specificity, lymph node 
tissue  sections were  tested  with  Fas-L antisera,  and virtually all 
cells were completely negative with positive cells being restricted 
to  small intensely stained clusters within the nodal parenchyma. 
The staining pattern obtained with Fas receptor antibody was also 
largely negative, except for a thin rim of positive cells which were 
localized to the lymph node subcapsular region. As an additional 
negative control, tissue sections from one of the non-inflamma- 
tory  neurologic  control  brains which  had  no  positive  staining 
cells was routinely included in each experiment. 
Fas/APO 1 (CD95) Receptor  Detection.  The slides for Fas/APO1 
receptor detection were processed exactly as described for Fas-L 
except  that  a  mouse monoclonal anti-human Fas  receptor  anti- 
body at 10 I.tg/ml was used as the primary antibody (Oncor, Inc., 
Bethesda, MD). 
In Situ TUNEL Detection.  We  used  a  modification  of  the 
TUNEL procedure (7) in which cells containing fragmented DNA 
are  labeled  with  digoxigenin-11-dUTP  and  subsequently  de- 
tected by an immunoperoxidase localization system.  The in situ 
experiments were  performed  using kits  purchased  from  Oncor 
(ApopTag kit)  with  minor modifications to  the  manufacturer's 
directions and no counterstain was usually employed. When test- 
ing 3-b~m-thick paraffin-embedded sections, we greatly curtailed 
the suggested deproteinization times with proteinase K  (0-10 rain) 
and reduced the terminal deoxynucleotidyl transferase  (TdT) incu- 
bation time from the suggested 60 rain to a range of 3-60 rain. 
FITC-fluorescent TUNEL labeling was used in several co-local- 
ization experiments and these sections were evaluated by confocal 
microscopy.  For these  experiments, the  Fas-L second label was 
visualized with a Cy3 anti-rabbit detection system. 
Double Staining Immunohistochemistry.  The  ABC  system  was 
used  for  glial cell  marker  immunocytochemistry following the 
Fas-L detection procedure  and visualization of the  Fas  reaction 
products with diaminobenzidine. Monoclonal primary antibody 
against astrocyte-specificc  glial fibrillary acidic  protein  (GFAP); 
dilution 1:300, undiluted Human NK marker (HNK-1) (Becton- 
Dickinson,  Mountain View,  CA)  against  oligodendroglia,  and 
CD-3 pan T  cell marker; dilution 1:1,200 (all from Dako Corp., 
Carpenteria, CA) was applied overnight at 4~  The slides were 
rinsed and incubated for 30 rain with biotinylated secondary anti- 
body  and  the  procedure  repeated  with  peroxidase-conjugated 
avidin-biotin complex  (Elite Peroxidase  ABC kit; Vector Labs., 
Inc., Burlingame, CA). Reaction product on double-labeled cells 
was  visualized with Vector  SG chromagen.  The monocyte lin- 
eage-specific RCA-1  biotinylated lectin probe;  dilution  1:1500 
(Vector Labs.) was reacted for 1 h and reactions in the absence of 
primary antibody were used to control for nonspecific binding. 
Fas  ligand-labeled cells  were  quantified by two  observers by 
light microscopy and video projection using a  24-mm eyepiece 
disk reticle (5  ￿  5  mm in 1-mm subdivisions) calibrated with a 
stage micrometer.  10 fields (0.1  mm  2) from areas  with maximal 
signal were quantified at 20￿  magnification. The number of Fas- 
L-bearing cells in the MS group was compared to the two control 
groups by the Kruskal-Wallis one way analysis of variance and the 
Mann Whitney U  test. For double labeled cells, an average of 138 
cells  labeled for  each glial-specific marker were scored for pres- 
ence of the second (Fas ligand) label and expressed as a percentage 
of the total number counted. 
Results 
Quantification of Fas-L in MS Plaques.  We  first  investigated 
whether  or  not  Fas-L  could  be  detected  in sections  from 
chronic  plaques  of MS  white  matter  and  from  non-MS 
control brains by immunohistochemistry. Fig.  1 shows that 
of 16 chronic MS plaques tested  12 lesions had many more 
cells reacting with Fas-L antibody than control brains from 
neurologic conditions without inflammation where  4  of 5 
brains were completely negative. The most reactive areas of 
the  MS  lesions on average  had  190  Fas-L-positive cells in 
an  area  of 1  mm  2  and  the  two  acute  plaques  had  much 
higher values. In contrast to the non-inflammatory control 
brains, 4  of 6 brains from neuropathologic conditions associ- 
Figure  1.  Graph  quantifying  number of Fas-L-positive cells in MS 
brains and two control  groups. The two acute plaques are indicated by 
open circles (-o-).  The non-MS brains have been subdivided into non- 
inflammatory brain controls (Non-inflam) and an inflammatory group (In- 
flam) which includes chronic  measles infection,  subacute sclerosing pa- 
nencephalitis (SSPE), progressive multifocal leucoencephalopathy (PML), 
acute hemorrhagic encephalomyelitis (AHLE), and CNS HIV infection. 
The  MS  group  is significantly different from  all  other groups  by the 
Kruskal-Wallis one way analysis  of variance P =  0.02, and MS tissues also 
contain significantly more  Fas-L-positive  cells than  non-inflammatory 
controls (P =  0.001, Mann-Whitney  U test). Four non-MS controls with 
marked CNS inflammatory  disease also had elevated numbers of Fas-L-pos- 
itive cells. 
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Figure  2.  Identity of Fas-L-positive cells in chronic MS lesions. (Top 
left), Fas-L (brown stain) co-labeled with P,  CA-1 lectin for macrophage/ 
microglia lineage cells (blue stain). A large double labeled macrophage is 
visible on the left. Three smaller round cells which morphologically ap- 
pear to be Fas-L-positive oligodendrocytes are also present, Magnification 
X400. (Bottom left) Co-localization Fas-L experiment using an astrocyte 
marker - glial fibrillary acidic protein (GFAP) (blue stain). Double labeled 
astrocytes are present as well as numerous non-GFAP-positive cells which 
are heavily labeled by Fas-L antibody (brown  stain). Magnification X200. 
(Right)  Co-localization  with  oligodendroglia-specificc marker  HNK-1 
(blue stain).  Many  Fas-L HNK-l-positive  oligodendroglia are  present 
within the MS brain. Magnification >(200. 
ated with inflammation clearly also had clusters of Fas-L-pos- 
itive  cells  within  their  white  matter  lesions.  Three  of the 
four  positive  inflammatory  brains  were  from  conditions 
where  multiple  foci  of primary  demyelination  are  com- 
mon.  Two  were  associated with  chronic  CNS  viral infec- 
tions  (SSPE  and  PML)  and  the  third  patient  had  acute 
hemorrhagic  encephalitis,  a primary demyelinating  disease. 
Nerve cells served as an additional internal negative control 
for antibody  specificity since  they were  consistently  Fas-L 
negative in all brains tested. 
Identification  of Fas Ligand-positive  Cells in MS  Brain.  The 
identity of Fas-L-positive cells in chronic MS lesions was de- 
temained by co-localization staining with markers specific for 
monocytic lineage  (macrophage/microglia  [lectin/R.CA  1]), 
astrocytes  (GFAP),  and  oligodendroglia  (HNK  1).  Fig.  2 
shows  photomicrographs  obtained  when  Fas-L-positive 
MS  brain  was dual labeled with  the  cell  markers described 
above.  The figure illustrates that several different cell types 
within  MS  lesions  bear the  Fas ligand.  A  few ligand-posi- 
tive cells were  reactive with lectin  indicating  they were  of 
monocytic  lineage  (upper  left),  but  Fas-L-positive  resident 
glial cells of either astrocytic or oligodendrogial origin were 
much more common  (Fig.  2,  lower left and right).  The pop- 
ulation profile of Fas-L-positive cells by cell type was quan- 
tified in chronic MS plaques and these results are shown in 
Fig. 3.  The data confirms that the pattern of Fas-L-reactive 
cells  in  chronic  lesions  was  complex  composed  mostly  of 
ligand-positive  resident  glial  cells  with  a  small  overlay  of 
Fas-L-reactive macrophages.  While  many CD3-positive  T 
cells were readily detectable in a SSPE control brain known 
CELL TYPE 
Figure 3.  Quantification of Fas-L-labeled cells in chronic MS plaques 
by cell type. Identity of cells was accomplished by double labeling with 
cell-specific markers as described for Fig. 2. The majority of Fas-L labeled 
cells were  either  HNK  1-positive oligodendroglia (Oligo) or astrocytes 
(Astro). Macrophage hneage cells also consistently  labeled with Fas-L anti- 
body but always in much smaller numbers than resident glia. 
to  contain  extensive  T  cell  infiltrates,  CD3  reactive  cells 
were rarely found in chronic MS plaques and were detected 
in only two chronic MS brains. 
The  complex  pattern  characteristic  of MS  lesions  was 
clearly  not  present  in  two  of the  inflammatory  non-MS 
control brains  where  increased  numbers  of heavily labeled 
Fas-L cells were also present.  The labeled cells were mainly 
of macrophage  origin  (>90%)  in  the  white  matter lesions 
from  the  child  with  chronic  measles  infection  (SSPE)  and 
the  labeled  cells  in  the  adult  PML  brain  could  be  readily 
distinguished  from  the  MS  pattern  because  Fas-L  staining 
was largely restricted  to white matter cells with viral inclu- 
sions  (>90%).  The  pattern  of Fas-L-positive  cells in acute 
hemorrhagic  encephalomyelitis,  a  primary  demyelinating 
disease, was complex as seen in MS. These findings in three 
other  conditions  with  demyelinating  lesions  suggest  that 
the  potential  for involvement  of the  Fas  death  pathway is 
not  restricted  to MS  and  may be the preferred pathway of 
killing  for  other  inflammatory  diseases  with  white  matter 
pathology. 
Fas/Apo  1  (CD95)  Receptor  Expression  in  Diseased  Brain. 
We next investigated to what extent Fas/Apo  1 (CD95)  re- 
ceptor was expressed in MS brains and non-MS  controls as 
judged  by immunohistochemistry  because  the  demonstra- 
tion of Fas ligand without its cognate receptor being present 
in the diseased area of the brains would be difficult to inter- 
pret.  Fig.  4  shows that remarkably large numbers  of strongly 
reactive  Fas  receptor-positive  cells  including  some  with 
glial  cell  morphologic  characteristics  were  present  within 
an acute white matter MS lesion, and the edematous plaque 
also  contained  numerous  phagocytic  macrophages  which 
had engulfed  Fas-positive cells.  The presence  ofphagocy- 
tosed Fas-positive corpses in the MS lesion suggests that the 
Fas system is likely involved in the MS white matter patho- 
logic  process.  Smaller  numbers  of strongly labeled  Fas  re- 
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MS white matter plaque (brown stain). Many intensely stained receptor- 
positive individual cells and phagocytic macrophages  containing several 
ingested Fas receptor-positive  cells are present within the lesion (arrows). 
Magnification ￿ 
Figure 5.  Confocal microscopy  of Fas-L-positive  MS plaques which 
have been previously FITC-labeled  by the TUNEL procedure for frag- 
mented DNA and then dual labeled for Fas hgand. (Left) Numerous Fas- 
L-positive cells have been detected by Cy3 (red label) and two dying cells 
are visible  which were detected by the TUNEL assay (yellow signal). The 
fluorescent yellow staining cells (arrows) show good co-localization with 
cytoplasmic Fas ligand. Magnification X630. (Right) Higher magnifica- 
tion of another co-locahzation experiment  showing two more TUNEL- 
positive cells with Fas-L-positive  cytoplasm. 
ceptor  expressing  cells  were  present  in  three  of  four 
chronic plaques tested and we also  found extremely wide- 
spread expression of Fas receptor, albeit with lesser intensity, 
in  many  non-MS  neuropathologic  conditions  of diverse 
etiology including malignant glioblastoma multiforme, Alz- 
heimer's  and  Parkinson's  disease,  cerebrovascular  disease, 
and chronic CNS infectious processes including HIV, mea- 
sles infection (SSPE),  and JC-papovavirus infection (PML). 
These findings on non-MS brains indicate that whereas Fas 
receptor has been  reported  to  be  constitutively  absent  or 
weakly expressed in normal mouse and human brain paren- 
chyma (8), brain is readily induced to express this receptor 
by a variety of pathologic stimuli (9). The Fas receptor up- 
regulation  we  have  detected  in  several  of our  non-MS 
brain controls has been previously reported (10-13). 
Fas-L  Co-localizes  with  TUNELopositive  Cells  in  MS  Brain. 
To examine the possibility that the Fas pathway contributes 
to  cell  killing in  MS  white  matter,  we  first  employed an 
FITC-immunofluorescent in situ TUNEL assay which de- 
tects low molecular weight fragmented DNA within dying 
cells.  Slides from several TUNEL-positive chronic MS le- 
sions were subsequently dual labeled with  the  Fas-L anti- 
serum which was visualized with a  Cy3 detection system. 
The  slides  were  evaluated by laser scanning  confocal mi- 
croscopy and  as shown in  Fig.  5,  numerous  Cy3-positive 
red staining  Fas-L cells  were found.  The figure also  illus- 
trates  that  the  yellow FITC-TUNEL-positive dying  cells 
showed good co-localization with presence of Fas-L.  The 
converse  experiment  in  which  TUNEL-positive  lesions 
were dual labeled for Fas receptor similarly showed that the 
dying cells  also  displayed the  Fas/Apo  1  (CD 95)  receptor 
(data not shown). These findings indicate that attack of re- 
ceptor-positive cells  by Fas-L is possible in  MS brain and 
that Fas/Fas-L mediated killing could be an important fac- 
tor in the destruction of MS white matter. 
Discussion 
Evidence  is  rapidly  accumulating  that  the  Fas/Apo  1 
(CD95)/Fas-L system is an important pathway responsible 
for the induction  of cell death by apoptosis in homeostasis 
and disease states within several diverse tissues.  Fas receptor 
(CD95) is a cell surface glycoprotein member of the tumor 
necrosis  factor/nerve  growth  factor  receptor  superfamily 
and is widely expressed throughout the body (8, 9). Fas re- 
ceptor can be readily induced by cytokines such as TNF-~x 
and interferon-~ in some tissues  including glial  cells where 
it is not constitutively expressed (13,  14). A cytoplasmic re- 
gion called the "death domain" is present on the Fas recep- 
tor which  shows strong homology with  a  similar domain 
on  the  TNF-tL  l  (15).  This  highly  conserved  domain  is 
necessary  and  sufficient  for transduction  of the  apoptotic 
signal (16). 
The evidence to date indicates that Fas ligand, the other 
member of the pair, is much more restricted in its distribu- 
tion  and  is  constitutively  expressed mainly in  T  cell-rich 
organs (17,  18),  stroma cells  of the eye, and the testes (19, 
20).  Fas-L expression can be upregulated in cytotoxic T  cells, 
NK cells,  and the TH1 subset of T  helper cells.  These acti- 
vated T  cells can generate both membrane bound and solu- 
ble forms of Fas-L (sFas-L) which in certain leukemia/lym- 
phoma patients achieves measurable serum levels (21).  The 
patients with high levels of sFas-L are neutropenic and some 
have hepatic damage (22).  The Fas pathway is thought to 
be important  in  controlling  the  rapid  turnover of mature 
neutrophils by apoptosis (23).  Several additional lines of ev- 
idence point to a role for accelerated Fas mediated destruc- 
tion of liver tissue infected with hepatitis B  or hepatitis  C 
(24,  25). The Fas receptor/Fas-L system also plays a critical 
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the periphery as demonstrated in vivo by the enlarged lym- 
phoid organs and enhanced lymphoproliferation present in 
lpr/lpr  mutant  mice  which  are  defective  in  Fas  receptor 
(26-29). 
In this report, we present evidence that significant num- 
bers of glial cells within MS plaques bear the cytotoxic ef- 
fector molecule Fas-L.  Of equal importance,  ~30% of the 
positive  cells  belong to  an  HNK-l-positive  oligodendro- 
glial  population.  This  glial  cell is  responsible  for the  pro- 
duction and support  of myelin within  the  central nervous 
system. We also showed immunohistochemical evidence of 
widespread  Fas receptor upregulation  in the  same  MS  le- 
sions, indicating that both Fas death system components are 
available for interaction  and possible  Fas  mediated cell de- 
struction. The co-localization of TUNEL-positive dying cells 
with  Fas-L,  and  the  presence  of numerous  Fas-receptor- 
positive  corpses  within  lesional  macrophages  support  the 
notion that Fas receptor carrying cells are indeed a target of 
Fas-L attack in MS lesions. 
The  precise  pathway  for  Fas  signaling  in  brain  white 
matter has not yet been studied.  However, a recent report 
on Fas  mediated  apoptosis in mouse w4 transformed  cells 
(which  constitutively  express  mouse  Fas  receptor)  found 
that  Fas  activation  initially  stimulates  ICE-like  proteases, 
and then  CPP32-1ike proteases  downstream  to induce the 
morphologic changes and DNA fragmentation pattern typ- 
ical  of apoptosis  (30).  This  in  vitro  Fas-mediated  process 
could be readily blocked by specific inhibitors  of ICE and 
CPP32 family proteases indicating that if a role for Fas in- 
volvement and its pathway can be defined in MS, it may be 
possible to block the Fas-L-induced destruction by inhibi- 
tion of the intracellular protease families mentioned above, 
solubilized Fas receptor, or other pharmacologic means. 
We thank Noounanong Cheewatrakoolpong for expert technical assistance. 
This work was supported  by VA grant 0013 of the Research Service of the Department of  Veterans Affairs. 
Address  correspondence  to  Peter  Dowling,  Deptartment  of Neurosciences,  UMD-New Jersey  Medical 
School,  185 South Orange Ave., University Heights, Newark, NJ 07103-2714. 
Received for publication  12June  1996 and in revised form 29July  1996. 
Note added in proof: Since acceptance by the journal, a more detailed manuscript  on cell death and birth in 
multiple sclerosis brain has been accepted by the Journal of Neurological Science (Dowling, P., W. Husar, J. 
Menonna, H. Donnenfeld, S. Cook, and M. Sidhu.  1996. Cell death and birth in multiple sclerosis brain../. 
Neurol. Sci. In press). 
References 
1. ffrench-Constant, C. 1994. Pathogenesis  of multiple  sclerosis. 
Lancet. 343:271-275. 
2.  Hailer,  D.,  and  H.  Weiner.  1995.  Immunological mecha- 
nisms  and therapy in multiple  sclerosis. ImmunoI.  Reu.  144: 
75-107. 
3.  Martin, R., and H. McFarland.  1995.  Immunological aspects 
of experimental allergic encephalomyelitis and multiple  scle- 
rosis. Crit.  Rev.  Clin.  Lab. &i. 32:121-182. 
4.  Merrill, J., D. Kono, J. Clayton, D. Ando, D. Hinton, and F. 
Hofman. 1992. Inflammatory leukocytes and cytokines in the 
peptide-induced disease of experimental  allergic  encephalo- 
myelitis in SJL and B10.PL mice. Proc. Natl. Acad.  Sci. USA. 
89:574-579. 
5.  Rieckmann,  P.,  M.  Albrecht,  B.  Kitze,  T.  Weber,  H.  Tu- 
mani, A. Broocks, W. Luer, A. Helwig, and S. Poser.  1995. 
Tumor necrosis  factor-o~ messenger  RNA expression  in pa- 
tients  with relapsing-remitting multiple  sclerosis is associated 
with disease activity. Ann. Neurol. 37:82-88. 
6.  Dowling, P.,  S. Bansil, J. Menonna, W. Husar,  and S. Cook. 
1995. Programmed cell death in multiple  sclerosis brain. Ann. 
Neurol. 38:341.  (Abstr.) 
7.  Gavrielli,  Y., Y. Sherman, and S. Ben-Sasson.  1992. Identifi- 
cation ofprogramrned cell death in situ via specific labeling of 
nuclear DNA fragmentation.J.  Cell Biol. 119:493-501. 
8.  Watanabe-Funkunaga,  R.,  C.  Brannan,  N.  Itoh,  S.  Yone- 
hara,  N.  Copeland,  N. Jenkins,  and  S.  Nagata.  1992.  The 
cDNA structure,  expression,  and chromosomal assignment  of 
the mouse Fas antigen.J.  Immunol.  148:1274-1279. 
9.  Leithauser,  F., J.  Dhein,  G.  Mechtersheimer,  K.  Koretz,  S. 
Bruderlein,  C. Henne, A. Schmidt, K. Debatin, P. Krammer, 
and P. Moiler.  1993.  Constitutive and induced expression  of 
APO-1, a new member of the nerve growth factor/tumor 
necrosis factor receptor superfamily,  in normal and neoplastic 
cells. Lab. Invest. 69:415-429. 
10. Matsuyama,  T., R. Hata,  M. Tagaya, Y. Yamamoto, T. Na- 
kajima, J.  Furuyama, A. Wanaka,  and M.  Sugita.  1994.  Fas 
antigen  mRNA  induction  in  postischemic  murine  brain. 
Brain Res. 657:342-346. 
11. Nishimura,  T.,  H.  Akiyama,  S.  Yonehara,  H.  Kondo,  K. 
Okeda, M. Kato, E.  Iseki, and K. Kosaka.  1995.  Fas antigen 
expression  in brains of patients  with Alzheimer-type demen- 
tia. Brain Res.  695:135-145. 
12. Tachibana,  O.,  H.  Nakazawa, J.  Lampe,  K.  Watanabe,  P. 
Kleihues,  and  H.  Ohgaki.  1995.  Expression  of Fas/APO-1 
during the progression of astrocytomas.  Cancer Res. 55:5528- 
5530. 
13. Weller, M., K. Frei, P. Groscurth,  P. Krammer,  Y. Yonekawa, 
and A.  Fontana.  1994.  Anti-Fas/APO-1  antibody-mediated 
apoptosis of cultures  human glioma cells: induction and mod- 
ulation of  sensitivity by cytokines.J. Clin.  Invest. 94:954-964. 
14. Moiler,  P., K. Koretz,  F. Leithauser, S. Bruderlein,  C. Henne, 
A. Quentmeier,  and P. Krammer.  1994. Expression of APO-1 
1517  Dowling et al.  Brief Definitive Report (CD95),  a member of the NGF/TNF receptor superfamily, 
in normal and neoplastic colon epithelium. Int. J.  Cancer. 57: 
371-377. 
15. Nagata, S., and P. Goldstein. 1995.  The Fas death factor. Sci- 
ence (Wash. DC). 267:1449-1456. 
16. Tartaglia, L., T. Ayres, G. Wong, and D. Goeddel. 1993.  A 
novel  domain within  the  55  kd  TNF  receptor signals  cell 
death. Ceil. 74:845-853. 
17. Suda,  T.,  T.  Takahashi,  P.  Golstein, and  S.  Nagata.  1993. 
Molecular cloning and expression of the Fas ligand: a novel 
member of the tumor necrosis factor family. Cell.  75:1168- 
1178. 
18. Suda,  T.,  T.  Okazaki,  Y.  Naito,  T.  Yokota,  N.  Arai,  S. 
Ozaki, K. Nakao, and S. Nagata. 1995. Expression of the Fas 
ligand in T-ceU lineage. J. Immunol.  154:3806-3813. 
19. Griffith, T., T. Brunner,  S. Fletcher, D. Green, and T. Fer- 
guson. 1995.  Fas ligand-induced apoptosis as a mechanism of 
immune privilege. Science (Wash. DC). 270:1189-1192. 
20. Bellgrau, D., D. Gold, H. Selaway, J. Moore, A. Franzosoff, 
and R.  Duke.  1995.  A  role for CD95  ligand in preventing 
graft rejection. Nature (Lond.).  377:630-632. 
21. Tanaka, M., T. Suda, T. Takahashi, and S. Nagata. 1995. Ex- 
pression of the functional soluble form of human Fas ligand 
in activated lymphocytes. EMBO  (Eur.  Mol.  Biol.  Organ.)J. 
14:1129-1135. 
22.  Tanaka,  M.,  T.  Suda,  K.  Haze,  N.  Namura,  K.  Sato,  F. 
Kimura, K. Motoyoshi, M. Mizuki, S. Tagawa, S. Ohga et al. 
1996.  Fas ligand in human serum. Nat. Med. 2:317-322. 
23.  Iwai, K., T. Miyawaki, T. Takizawa, A. Konno, K. Ohta, A. 
Yachie,  H.  Seki, and N.  Taniguchi.  1994.  Differential ex- 
pression of bcl-2 and susceptibility to anti-Fas-mediated cell 
death in peripheral blood lymphocytes, monocytes, and neu- 
trophils. Blood.  84:1201-1208. 
24. Galle, P., W. Hofman, H. Walczak, H. Schaller, G. Otto, W. 
Stremmel, P. Krammer, and L. Runkel.  1995.  Involvement 
of the CD95  (APO-1/Fas) receptor and ligand in liver dam- 
age..]. Exp. Med.  182:1223-1230. 
25. Mita,  E.,  N.  Hayashi,  S.  Ito,  T.  Takehara,  T.  I-Iijioka, A. 
Kasahara,  H.  Fusamoto, and T.  Kamada.  1994.  Role of Fas 
ligand in apoptosis induced by Hepatitis C  virus infection. 
Biochem.  Biophys.  Res. Commun.  204:468-474. 
26.  Dhein, J., H. Walczak, C. Baumer, K. Debatin, and P. Kram- 
mer. 1995. Autocrine T cell suicide mediated by APO-1 (Fas/ 
CD95). Nature (Lond.).  373:438-441. 
27. Brunner, T., R. Mogil, D. LaFace, N. Yoo, A. Mahoubl, F. 
Echeverri, S. Martin, W. Force, D. Lynch, C. Ware, and D. 
Green. 1995.  Cell-autonomous Fas (CD95)/Fas-ligand inter- 
action mediates activation-induced apoptosis in T-cell hybri- 
domas. Nature (Lond.).  373:441-444. 
28. Ju, S.-T., D. Panka, H. Cul, R. Ettinger, M. E1-Khabib, D. 
Sherr,  B.  Stanger,  and  A.  Marshak-Rothstein.  1995.  Fas 
(CD95)/FasL  interactions  required  for  programmed  cell 
death after T cell activation. Nature (Lond.).  373:444-448. 
29.  Watanabe-Fukunaga, R., C. Brannan, N. Copeland, N. Jen- 
kins, and S.  Nagata.  1992.  Lymphoproliferation disorder in 
mice explained by defects in Fas antigen that mediates apop- 
tosis. Nature (Lond.).  356:314-317. 
30. Enari, M., R. Talanian, W. Wong, and S. Nagata. 1996.  Se- 
quential  activation  of ICE-like  and  CPP32-1ike  proteases 
during Fas-mediated apoptosis. Nature (Lond.).  380:723-726. 
1518  Fas-Receptor/Ligand System in MS Lesions 